Cross-talk of MicroRNA and hydrogen sulfide: A novel therapeutic approach for bone diseases
- PMID: 28618652
- PMCID: PMC5562148
- DOI: 10.1016/j.biopha.2017.06.007
Cross-talk of MicroRNA and hydrogen sulfide: A novel therapeutic approach for bone diseases
Abstract
Bone homeostasis requires a balance between the bone formation of osteoblasts and bone resorption of osteoclasts to maintain ideal bone mass and bone quality. An imbalance in bone remodeling processes results in bone metabolic disorders such as osteoporosis. Hydrogen sulfide (H2S), a gasotransmitter, has attracted the focus of many researchers due to its multiple physiological functions. It has been implicated in anti-inflammatory, vasodilatory, angiogenic, cytoprotective, anti-oxidative and anti-apoptotic mechanisms. H2S has also been shown to exert osteoprotective activity through its anti-inflammatory and anti-oxidative effects. However, the underlying molecular mechanisms by which H2S mitigates bone diseases are not completely understood. Experimental evidence suggests that H2S may regulate signaling pathways by directly influencing a gene in the cascade or interacting with some other gasotransmitter (carbon monoxide or nitric oxide) or both. MicroRNAs (miRNAs) are short non-coding RNAs which regulate gene expression by targeting, binding and suppressing mRNAs; thus controlling cell fate. Certainly, bone remodeling is also regulated by miRNAs expression and has been reported in many studies. MicroRNAs also regulate H2S biosynthesis. The inter-regulation of microRNAs and H2S opens a new possibility for exploring the H2S-microRNA crosstalk in bone diseases. However, the relationship between miRNAs, bone development, and H2S is still not well explained. This review focuses on miRNAs and their roles in regulating bone remodeling and possible mechanisms behind H2S mediated bone loss inhibition, H2S-miRNAs crosstalk in relation to the pathophysiology of bone remodeling, and future perspectives for miRNA-H2S as a therapeutic agent for bone diseases.
Keywords: Bone remodeling; Hydrogen sulfide; Osteoblast; Osteoclast; Osteoporosis.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
The authors have declared no conflict of interest.
Figures
Similar articles
-
Emerging role of hydrogen sulfide-microRNA crosstalk in cardiovascular diseases.Am J Physiol Heart Circ Physiol. 2016 Apr 1;310(7):H802-12. doi: 10.1152/ajpheart.00660.2015. Epub 2016 Jan 22. Am J Physiol Heart Circ Physiol. 2016. PMID: 26801305 Free PMC article. Review.
-
Atherosclerosis and the Hydrogen Sulfide Signaling Pathway - Therapeutic Approaches to Disease Prevention.Cell Physiol Biochem. 2017;42(3):859-875. doi: 10.1159/000478628. Epub 2017 Jun 23. Cell Physiol Biochem. 2017. PMID: 28641276 Review.
-
Hydrogen Sulfide Promotes Bone Homeostasis by Balancing Inflammatory Cytokine Signaling in CBS-Deficient Mice through an Epigenetic Mechanism.Sci Rep. 2018 Oct 15;8(1):15226. doi: 10.1038/s41598-018-33149-9. Sci Rep. 2018. PMID: 30323246 Free PMC article.
-
Treatment with hydrogen sulfide attenuates sublesional skeletal deterioration following motor complete spinal cord injury in rats.Osteoporos Int. 2017 Feb;28(2):687-695. doi: 10.1007/s00198-016-3756-7. Epub 2016 Sep 3. Osteoporos Int. 2017. PMID: 27591786
-
Regulation of Bone Metabolism by microRNAs.Curr Osteoporos Rep. 2018 Feb;16(1):1-12. doi: 10.1007/s11914-018-0417-0. Curr Osteoporos Rep. 2018. PMID: 29335833 Review.
Cited by
-
Role of Hydrogen Sulfide in Oncological and Non-Oncological Disorders and Its Regulation by Non-Coding RNAs: A Comprehensive Review.Noncoding RNA. 2024 Jan 18;10(1):7. doi: 10.3390/ncrna10010007. Noncoding RNA. 2024. PMID: 38250807 Free PMC article. Review.
-
Whole-Blood MicroRNA Sequence Profiling and Identification of Specific miR-21 for Adolescents With Postural Tachycardia Syndrome.Front Neurosci. 2022 Jun 30;16:920477. doi: 10.3389/fnins.2022.920477. eCollection 2022. Front Neurosci. 2022. PMID: 35844239 Free PMC article.
-
Treadmill exercise influences the microRNA profiles in the bone tissues of mice.Exp Ther Med. 2021 Sep;22(3):1035. doi: 10.3892/etm.2021.10467. Epub 2021 Jul 19. Exp Ther Med. 2021. PMID: 34373721 Free PMC article.
-
Association of Hydrogen Sulfide with Femoral Bone Mineral Density in Osteoporosis Patients: A Preliminary Study.Med Sci Monit. 2021 Mar 14;27:e929389. doi: 10.12659/MSM.929389. Med Sci Monit. 2021. PMID: 33714972 Free PMC article.
-
Strontium Ameliorates Glucocorticoid Inhibition of Osteogenesis Via the ERK Signaling Pathway.Biol Trace Elem Res. 2020 Oct;197(2):591-598. doi: 10.1007/s12011-019-02009-6. Epub 2019 Dec 12. Biol Trace Elem Res. 2020. PMID: 31832923
References
-
- Larsson S, Fazzalari NL. Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg. 2014;134(2):291–29. - PubMed
-
- Grassi F, Malik Tyagi A, Calvert JW, Gambari L, Walker LD, Yu M, Robinson J, Li JY, Lisignoli G, Vaccaro C, Adams J, Pacifici R. Hydrogen Sulfide Is a Novel Regulator of Bone Formation Implicated in the Bone Loss Induced by Estrogen Deficiency. J Bone Miner Res: Official J Am Soc Bone Miner Res. 2016;31(5):949–963. - PMC - PubMed
-
- Li L, Rose P, Moore PK. Hydrogen sulfide and cell signaling. Annu Rev Pharmacool Toxicol. 2011;51:169–187. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
